Sold as Parasal Sodium, Teebacin. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 22, 2026, FDA lists 5 applications for Aminosalicylate sodium (sold as Parasal Sodium, Teebacin), first approved Mar 8, 1950, with 0 new uses approved and 0 published complete response letters.
| Mar 8, 1950 | TeebacinNDA 7320 · New formulation or manufacturer | Consolidated Midland | 0 | Discontinued |
| Apr 14, 1971 | Sodium AminosalicylateANDA 80097 | Hexcel | 0 | Discontinued |
| Jan 17, 1978 | Sodium P.A.S.ANDA 80138 | Lannett | 3 | Discontinued |
| — | P.A.S. SodiumANDA 80947 | Century Pharmaceuticals | 0 | Discontinued |
| — | Parasal, Parasal SodiumNDA 6811 | Panray | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA